{"filing":{"accession_number":"0001213900-26-060556","cik":"0001840877","ticker":"COCHW","company_name":"Envoy Medical, Inc.","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"ea0292043-8k_envoy.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840877/000121390026060556/ea0292043-8k_envoy.htm"},"events":[{"id":10610,"run_id":9308,"accession_number":"0001213900-26-060556","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Envoy Medical received a Nasdaq staff determination on November 19, 2025, that its Class A Common Stock failed to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Although the company was granted an initial 180-day compliance period (until May 18, 2026) and subsequently a second 180-day period (until November 16, 2026), the filing explicitly discloses the failure to satisfy a continued listing rule and the delisting risk, which is the core substance of Item 3.01. This is material to investors as it directly threatens the company's continued listing on Nasdaq.","company_name":"Envoy Medical, Inc.","ticker":"COCHW","filing_date":"2026-05-22","submitted_at":null,"items":[{"id":6970,"accession_number":"0001213900-26-060556","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Envoy Medical received a Nasdaq staff determination on November 19, 2025, that its Class A Common Stock failed to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Although the company was granted an initial 180-day compliance period (until May 18, 2026) and subsequently a second 180-day period (until November 16, 2026), the filing explicitly discloses the failure to satisfy a continued listing rule and the delisting risk, which is the core substance of Item 3.01. This is material to investors as it directly threatens the company's continued listing on Nasdaq.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:52:13.162629+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6970,"accession_number":"0001213900-26-060556","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Envoy Medical received a Nasdaq staff determination on November 19, 2025, that its Class A Common Stock failed to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Although the company was granted an initial 180-day compliance period (until May 18, 2026) and subsequently a second 180-day period (until November 16, 2026), the filing explicitly discloses the failure to satisfy a continued listing rule and the delisting risk, which is the core substance of Item 3.01. This is material to investors as it directly threatens the company's continued listing on Nasdaq.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:52:13.162629+00:00","company_name":"Envoy Medical, Inc.","ticker":"COCHW","filing_date":"2026-05-22"}]}